Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Stem Cell Research

  Free Subscription


Articles published in Leuk Lymphoma

Retrieve available abstracts of 72 articles:
HTML format



Single Articles


    February 2024
  1. BARAJAS ORDONEZ F, Wolleschak D, Zeller Y, Hinnerichs M, et al
    Parameters of body composition do not predict survival in patients with multiple myeloma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2024 Feb 21:1-8. doi: 10.1080/10428194.2024.2319226.
    PubMed     Abstract available


  2. TANG K, Lipton JH
    Stem cell allografting for chronic Myeloid leukemia in the tyrosine kinase era - forgotten but not gone.
    Leuk Lymphoma. 2024 Feb 9:1-10. doi: 10.1080/10428194.2024.2313626.
    PubMed     Abstract available


    January 2024
  3. VIVIANI S, Vanazzi A, Frassoni S, Rusconi C, et al
    High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
    Leuk Lymphoma. 2024 Jan 2:1-12. doi: 10.1080/10428194.2023.2298273.
    PubMed     Abstract available


    December 2023
  4. ZHANG F, Hu GH, Zhang LP, Xu LP, et al
    Outcomes of haploidentical hematopoietic stem cell transplantation with 'Beijing protocol' in pediatric myeloid neoplasms post cytotoxic therapy: a case series study.
    Leuk Lymphoma. 2023 Dec 3:1-6. doi: 10.1080/10428194.2023.2281276.
    PubMed    


    November 2023
  5. LAI X, Xiao J, Wang T, Hou C, et al
    Prognostic significance of persisting DNMT3A, ASXL1, and TET2 mutation burden in acute myeloid leukemia patients with allogeneic hematopoietic stem cell transplantation during complete remission.
    Leuk Lymphoma. 2023 Nov 22:1-9. doi: 10.1080/10428194.2023.2284089.
    PubMed     Abstract available


  6. VERSTRAETE E, Baumann C, Rousseau H, Campidelli A, et al
    Comparison of two reduced intensity conditioning regimens: Flu-Bu2 versus RIC-TBF in allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 Nov 21:1-4. doi: 10.1080/10428194.2023.2281269.
    PubMed    


  7. ITONAGA H, Kato T, Sawayama Y, Katsuoka S, et al
    RAISING revealed a heterogenous pattern of HTLV-1 clonality after HLA-haploidentical peripheral blood stem cell transplantation for ATL.
    Leuk Lymphoma. 2023 Nov 1:1-4. doi: 10.1080/10428194.2023.2276058.
    PubMed    


    October 2023
  8. MERIC N, Albayrak E, Gulbas Z, Kocabas F, et al
    MEIS inhibitors reduce the viability of primary leukemia cells and Stem cells by inducing apoptosis.
    Leuk Lymphoma. 2023 Oct 30:1-12. doi: 10.1080/10428194.2023.2275532.
    PubMed     Abstract available


    September 2023
  9. LI L, Zhang R, Cao W, Bian Z, et al
    Comparative analysis of hypomethylating agents as maintenance therapy after allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Leuk Lymphoma. 2023 Sep 21:1-10. doi: 10.1080/10428194.2023.2252948.
    PubMed     Abstract available


  10. GAULIN C, Craig F, Fortin Ensign S, Robetorye R, et al
    Allogeneic hematopoietic stem cell transplantation in adults with dendritic/histiocytic neoplasms.
    Leuk Lymphoma. 2023 Sep 7:1-4. doi: 10.1080/10428194.2023.2255707.
    PubMed    


  11. PLATE M, Jessurun J, van Besien K
    Immune reconstitution inflammatory syndrome in a patient with M.haemophilum infection after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 Sep 7:1-3. doi: 10.1080/10428194.2023.2254875.
    PubMed    


  12. ELEUTHERAKIS PAPAIAKOVOU E, Terpos E, Kanellias N, Migkou M, et al
    Impact of daratumumab on stem cell mobilization and collection, engraftment and early post-transplant complications among multiple myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2023 Sep 1:1-8. doi: 10.1080/10428194.2023.2253479.
    PubMed     Abstract available


    August 2023
  13. VELY A, Couturier MA, Delepine P, Le Calloch R, et al
    Comparison of efficacy and toxicity according to etoposide and cytarabine dosing in BEAM conditioning followed by autologous stem cell transplantation in Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Aug 24:1-10. doi: 10.1080/10428194.2023.2251073.
    PubMed     Abstract available


  14. KENKRE VP, Bradley K, Milton A, Burkholder JK, et al
    TCR-alpha/beta and CD19 depleted stem cell grafts from haploidentical donors for allogeneic transplantation in patients with relapsed lymphoma: a single-center experience.
    Leuk Lymphoma. 2023 Aug 10:1-5. doi: 10.1080/10428194.2023.2240918.
    PubMed    


  15. LEW TE, Cliff ERS, Dickinson M, Tam CS, et al
    Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease.
    Leuk Lymphoma. 2023 Aug 2:1-9. doi: 10.1080/10428194.2023.2241095.
    PubMed     Abstract available


    July 2023
  16. CHEN H, Zhao X, Pan W, Xiao H, et al
    Integrated genomic and single-cell transcriptomic analyses reveal clonal evolution and immune signature in donor cell leukemia after haploidentical allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 Jul 10:1-8. doi: 10.1080/10428194.2023.2232493.
    PubMed     Abstract available


    June 2023
  17. WOLFF L, Clottu A, Mamez AC, Ribi C, et al
    Myositis manifesting as respiratory insufficiency with anti-RNA polymerase III antibodies: an unusual presentation of graft-versus-host disease.
    Leuk Lymphoma. 2023 Jun 7:1-4. doi: 10.1080/10428194.2023.2220452.
    PubMed    


  18. NESR G, Shah R, Kyriakou C, Sive J, et al
    Impact of timing of stem cell return following high dose melphalan in multiple myeloma patients with renal impairment: a single center experience.
    Leuk Lymphoma. 2023 Jun 1:1-7. doi: 10.1080/10428194.2023.2216817.
    PubMed     Abstract available


    May 2023
  19. SHARMA N, Benson E, Zhao Q, Nunnelee J, et al
    Survival outcomes following autologous stem cell transplant with melphalan 140mg/m(2) versus 200mg/m(2) preparative regimens in patients with multiple myeloma.
    Leuk Lymphoma. 2023 May 18:1-7. doi: 10.1080/10428194.2023.2213366.
    PubMed     Abstract available


  20. MAGEAU A, Ambert-Balay K, Boutolleau D, Schuffenecker I, et al
    Norovirus and sapovirus infections after allogeneic hematopoietic stem cell transplantation: is it worth it to look for them?
    Leuk Lymphoma. 2023 May 10:1-9. doi: 10.1080/10428194.2023.2211186.
    PubMed     Abstract available


  21. PLANTE ME, Feng X, Boudreault JS
    Single-center retrospective study assessing the efficacy and safety of BeEAM (bendamustine, etoposide, cytarabine, melphalan) as conditioning regimen for autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2023 May 8:1-9. doi: 10.1080/10428194.2023.2203790.
    PubMed     Abstract available


  22. MODI D, Alkassis S, Kim S, Kin A, et al
    Allogeneic stem cell transplant outcomes between TBI-containing reduced intensity and myeloablative conditioning regimens for ALL in complete remission.
    Leuk Lymphoma. 2023 May 8:1-10. doi: 10.1080/10428194.2023.2206181.
    PubMed     Abstract available


    April 2023
  23. AKHMEDOV M, Klyasova G, Kuzmina L, Fedorova A, et al
    Impact of fluoroquinolone administration and gut mucosal colonization on the risk of pre-engraftment bloodstream infections after allogeneic hematopoietic cell transplantation.
    Leuk Lymphoma. 2023 Apr 22:1-10. doi: 10.1080/10428194.2023.2197532.
    PubMed     Abstract available


  24. MEHYAR LS, Hartog L, Kahwash SB, Abu-Arja R, et al
    Long term survivor of MOZ-p300 therapy-related acute myeloid leukemia after matched unrelated donor bone marrow transplantation.
    Leuk Lymphoma. 2023 Apr 20:1-4. doi: 10.1080/10428194.2023.2203287.
    PubMed    


  25. BERTON G, Arcani R, Tichadou A, Farnault L, et al
    Therapy-related myeloid neoplasms after 177Lu-DOTATATE therapy for metastatic neuroendocrine neoplasia: CPX-351 consolidated by allogeneic stem cells transplantation as applicable therapeutic strategy.
    Leuk Lymphoma. 2023 Apr 12:1-3. doi: 10.1080/10428194.2023.2199896.
    PubMed    


    February 2023
  26. CHOQUETTE T, Henson ES, Yang X, Johnston JB, et al
    A novel method to investigate drug resistance in the chronic lymphocytic leukemia (CLL) microenvironment: Analysis of CLL Cellular Environment and Response (ACCER).
    Leuk Lymphoma. 2023 Feb 19:1-13. doi: 10.1080/10428194.2023.2171729.
    PubMed     Abstract available


    January 2023
  27. LIN M, Wu X, Zhang L, Li L, et al
    Fotemustine, etoposide, cytarabine, and cyclophosphamide (FEAC) conditioning regimen for autologous stem cell transplantation in lymphoma.
    Leuk Lymphoma. 2023 Jan 19:1-8. doi: 10.1080/10428194.2023.2167492.
    PubMed     Abstract available


  28. GAUT D, Oliai C, Mead M
    Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series.
    Leuk Lymphoma. 2023 Jan 17:1-4. doi: 10.1080/10428194.2022.2151839.
    PubMed    


  29. KALOYANNIDIS P, Al Zayer M, Al Darweesh M, Al Batran M, et al
    Brentuximab vedotin plus bendamustine versus platinum-based regimens as 1st salvage therapy and 'bridge' to autologous hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma.
    Leuk Lymphoma. 2023 Jan 11:1-4. doi: 10.1080/10428194.2022.2164195.
    PubMed    


    November 2022
  30. MOYER AM, Hashmi SK, Kroning CM, Patnaik M, et al
    Clinical impact of KIR haplotypes in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Nov 30:1-8. doi: 10.1080/10428194.2022.2151838.
    PubMed     Abstract available


  31. KUMAR L, Sahoo RK, Kumar S, Baa AK, et al
    Autologous stem cell transplant for multiple myeloma: Impact of melphalan dose on the transplant outcome.
    Leuk Lymphoma. 2022 Nov 23:1-10. doi: 10.1080/10428194.2022.2148214.
    PubMed     Abstract available


  32. PIANKO MJ
    Impact of diet and antibiotics on gut microbiota and outcomes in patients with multiple myeloma treated with autologous hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Nov 18:1-2. doi: 10.1080/10428194.2022.2148219.
    PubMed    


  33. MCCLELLAND J, Wong E, Grigg A
    Optimizing the oral dose of cyclosporine with concomitant posaconazole post stem cell allograft.
    Leuk Lymphoma. 2022 Nov 11:1-5. doi: 10.1080/10428194.2022.2142054.
    PubMed     Abstract available


  34. KREFT A, Schulze L, Ries I, Schindeldecker M, et al
    Histological diagnosis of acute graft-versus-host disease in different sites of the upper gastrointestinal tract with correlation to endoscopic findings.
    Leuk Lymphoma. 2022 Nov 6:1-7. doi: 10.1080/10428194.2022.2142056.
    PubMed     Abstract available


  35. MIKULSKI D, Koscielny K, Nowicki M, Wawrzyniak E, et al
    Neutrophil to lymphocyte ratio (NLR) impact on the progression-free survival and overall survival of multiple myeloma patients treated with high-dose chemotherapy and autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Nov 1:1-9. doi: 10.1080/10428194.2022.2136946.
    PubMed     Abstract available


    October 2022
  36. STEWART T, Dowling M, Janson B, Siderov J, et al
    Acute kidney injury in patients receiving high-dose etoposide phosphate as conditioning prior to hematopoietic stem cell transplantation in hematologic malignancies may be associated with elevated body mass index.
    Leuk Lymphoma. 2022 Oct 25:1-3. doi: 10.1080/10428194.2022.2136945.
    PubMed    


  37. GARDENSWARTZ A, Mehta B, El-Mallawany NK, van de Ven C, et al
    Safety and efficacy of combinatorial therapy utilizing myeloablative conditioning and autologous stem cell transplantation, targeted immunotherapy, and reduced intensity conditioning and allogeneic stem cell transplantation in children, adolescents, a
    Leuk Lymphoma. 2022 Oct 19:1-4. doi: 10.1080/10428194.2022.2133542.
    PubMed    


  38. D'ANGELO C, Sudakaran S, Asimakopoulos F, Hematti P, et al
    Perturbation of the gut microbiome and association with outcomes following autologous stem cell transplantation in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Oct 11:1-11. doi: 10.1080/10428194.2022.2131410.
    PubMed     Abstract available


    September 2022
  39. VILLALBA A, Gonzalez-Rodriguez AP, Arzuaga-Mendez J, Puig N, et al
    Single versus tandem autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma and high-risk cytogenetics. A retrospective, open-label study of the PETHEMA/Spanish Myeloma Group (GEM).
    Leuk Lymphoma. 2022 Sep 20:1-10. doi: 10.1080/10428194.2022.2123229.
    PubMed     Abstract available


  40. SHAHZAD M, Tariq E, Chaudhary SG, Anwar I, et al
    Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
    Leuk Lymphoma. 2022 Sep 15:1-9. doi: 10.1080/10428194.2022.2123228.
    PubMed     Abstract available


  41. LU Y, Xiong M, Sun RJ, Zhang JP, et al
    Comparisons of unmanipulated haploidentical donor, unrelated cord blood donor and matched unrelated donor hematopoietic stem cell transplantation in pediatric acquired severe aplastic anemia: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-10. doi: 10.1080/10428194.2022.2118527.
    PubMed     Abstract available


  42. LU Y, Sun RJ, Zhang JP, Xu F, et al
    Allogeneic hematopoietic stem cell transplantation with myeloablative conditioning regimen for blastic plasmacytoid dendritic cell neoplasm patients in complete remission: a single center study.
    Leuk Lymphoma. 2022 Sep 6:1-8. doi: 10.1080/10428194.2022.2118531.
    PubMed     Abstract available


    August 2022
  43. TARANTO E, Redd R, Jeter E, McHugh K, et al
    Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Aug 7:1-6. doi: 10.1080/10428194.2022.2103808.
    PubMed     Abstract available


    July 2022
  44. LOLLI G, Ursi M, Dicataldo M, Casadei B, et al
    Allogeneic stem cell transplantation is capable of healing a case of bone marrow aplasia following CAR-T cell therapy in a lymphoma patient.
    Leuk Lymphoma. 2022 Jul 22:1-3. doi: 10.1080/10428194.2022.2102622.
    PubMed    


  45. ZAMA D, Mondardini MC, Petris MG, Amigoni A, et al
    Pediatric cancer and hematopoietic stem cell transplantation patients requiring renal replacement therapy: results of the retrospective nationwide AIEOP study.
    Leuk Lymphoma. 2022 Jul 12:1-8. doi: 10.1080/10428194.2022.2095628.
    PubMed     Abstract available


    June 2022
  46. SERPENTI F, Sciume M, Galassi G, Saporiti G, et al
    Off-label venetoclax in combination with hypomethylating agents for post-allogeneic stem cell transplant acute myeloid leukemia relapse.
    Leuk Lymphoma. 2022 Jun 22:1-4. doi: 10.1080/10428194.2022.2090553.
    PubMed    


  47. LIU Y, Qi L, Wang T, Zhou B, et al
    The clinical outcomes of mixed engraftment patients treated with haploidentical stem cells combined with umbilical cord blood transplantation.
    Leuk Lymphoma. 2022 Jun 18:1-5. doi: 10.1080/10428194.2022.2086245.
    PubMed    


  48. HO M, Moscvin M, Low SK, Evans B, et al
    Risk factors for the development of orthostatic hypotension during autologous stem cell transplant in patients with multiple myeloma.
    Leuk Lymphoma. 2022 Jun 14:1-10. doi: 10.1080/10428194.2022.2084729.
    PubMed     Abstract available


  49. LAHOUD OB, Landau H, Nguyen J, Devlin S, et al
    Continuous induction with lenalidomide/dexamethasone versus autologous stem cell transplantation in newly diagnosed multiple myeloma: a case for response-adapted approach.
    Leuk Lymphoma. 2022 Jun 1:1-10. doi: 10.1080/10428194.2022.2062347.
    PubMed     Abstract available


    May 2022
  50. HOWELLS L, Chan WY, Sanchez E, Horder J, et al
    Patients with plasma cell disorders undergoing autologous stem cell transplant retain their humoral response to COVID-19 vaccination but falling titers emphasize the importance of re-vaccination.
    Leuk Lymphoma. 2022 May 14:1-5. doi: 10.1080/10428194.2022.2074989.
    PubMed    


  51. GERTZ MA, Warsame R, Muchtar E, Buadi F, et al
    Lack of a caregiver is associated with shorter survival in myeloma patients undergoing autologous stem cell transplantation.
    Leuk Lymphoma. 2022 May 12:1-6. doi: 10.1080/10428194.2022.2074993.
    PubMed     Abstract available


    April 2022
  52. PORRATA LF, Inwards DJ, Ansell SM, Micallef IN, et al
    Impact of autograft-absolute lymphocyte count on survival in double/triple hit lymphomas post-autologous stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 28:1-8. doi: 10.1080/10428194.2022.2064988.
    PubMed     Abstract available


  53. TAMAKI M, Nakasone H, Nakamura Y, Kawamura M, et al
    Risk factors and outcomes of definite or clinical idiopathic pneumonia syndrome after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2022 Apr 7:1-9. doi: 10.1080/10428194.2022.2057486.
    PubMed     Abstract available


    March 2022
  54. PERKINS B, Showel M, Schoch L, Imus PH, et al
    CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia.
    Leuk Lymphoma. 2022 Mar 27:1-7. doi: 10.1080/10428194.2022.2038375.
    PubMed     Abstract available


    February 2022
  55. MUKHERJEE A, Milton DR, Jabbour EJ, Gulbis AM, et al
    Clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
    Leuk Lymphoma. 2022 Feb 27:1-9. doi: 10.1080/10428194.2022.2043302.
    PubMed     Abstract available


  56. KAMADA Y, Arima N, Hayashida M, Nakamura D, et al
    Prediction of the risk for graft versus host disease after allogeneic hematopoietic stem cell transplantation in patients treated with mogamulizumab.
    Leuk Lymphoma. 2022 Feb 27:1-7. doi: 10.1080/10428194.2022.2043300.
    PubMed     Abstract available


  57. NAGAYAMA T, Fujiwara SI, Kikuchi T, Onda K, et al
    Impact of muscle mass loss assessed by computed tomography on the outcome of allogeneic stem cell transplantation.
    Leuk Lymphoma. 2022 Feb 14:1-7. doi: 10.1080/10428194.2022.2034159.
    PubMed     Abstract available


    January 2022
  58. WANG SSY
    Relationship between leukaemic stem cells and hematopoietic stem cells and their clinical application.
    Leuk Lymphoma. 2022 Jan 22:1-10. doi: 10.1080/10428194.2022.2027401.
    PubMed     Abstract available


  59. IKEDA D, Tsushima T, Fukumoto A, Kuzume A, et al
    Rapid liver atrophy and refractory ascites due to hepatoportal sclerosis in a patient after haploidentical stem cell transplantation.
    Leuk Lymphoma. 2022 Jan 12:1-4. doi: 10.1080/10428194.2022.2027400.
    PubMed    


    December 2021
  60. LU Y, Zhao YL, Xiong M, Sun RJ, et al
    Unmanipulated haploidentical donor and matched unrelated donor hematopoietic stem cell transplantation in patients with paroxysmal nocturnal hemoglobinuria: a single-center study.
    Leuk Lymphoma. 2021 Dec 16:1-9. doi: 10.1080/10428194.2021.2015588.
    PubMed     Abstract available


  61. SINGH V, Kim S, Deol A, Uberti JP, et al
    Allogeneic hematopoietic stem cell transplantation in T-cell lymphoma: a Meta-Analysis.
    Leuk Lymphoma. 2021 Dec 5:1-10. doi: 10.1080/10428194.2021.1999438.
    PubMed     Abstract available


    November 2021
  62. PALMIERI R, Buccisano F, Arena V, Irno Consalvo MA, et al
    CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.
    Leuk Lymphoma. 2021 Nov 21:1-5. doi: 10.1080/10428194.2021.2005042.
    PubMed    


  63. HOSOI H, Matsuyama Y, Murata S, Mushino T, et al
    Prolonged Epstein-Barr virus reactivation coincident with chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 16:1-4. doi: 10.1080/10428194.2021.2005047.
    PubMed    


  64. JADERSTEN M, Boriskina K, Lindholm C, Westrom S, et al
    Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation.
    Leuk Lymphoma. 2021 Nov 15:1-4. doi: 10.1080/10428194.2021.2002319.
    PubMed    


  65. SOARE DS, Radu E, Dumitru I, Vladareanu AM, et al
    Quantitative analyses of CD7, CD33, CD34, CD56, and CD123 within the FLT3-ITD/NPM1-MUT myeloblastic/monocytic bulk AML blastic populations.
    Leuk Lymphoma. 2021;62:2716-2726.
    PubMed     Abstract available


    October 2021
  66. ALHOMOUD M, Williams A, Magro C, Van Besien K, et al
    Use of eculizumab in autologous hematopoietic stem cell transplantation-associated thrombotic microangiopathy in two adults.
    Leuk Lymphoma. 2021 Oct 20:1-5. doi: 10.1080/10428194.2021.1992625.
    PubMed    


  67. ARCARI A, Morello L, Vallisa D, Marcheselli L, et al
    Allogeneic stem cell transplantation in patients with mantle cell lymphoma: results from the MANTLE-FIRST study on behalf of Fondazione Italiana Linfomi.
    Leuk Lymphoma. 2021 Oct 8:1-10. doi: 10.1080/10428194.2021.1961238.
    PubMed     Abstract available


  68. KOO RM, Ritchie D
    Self-reliance or the generosity of others?: autologous versus allogeneic stem cell transplantation in high-risk Hodgkin lymphoma.
    Leuk Lymphoma. 2021;62:2303-2305.
    PubMed    


    September 2021
  69. PAVIGLIANITI A, Sestili S, Bianchessi A, Memoli M, et al
    Stable pulmonary function after haploidentical stem cell transplantation with post-transplant cyclophosphamide: a single center experience.
    Leuk Lymphoma. 2021 Sep 29:1-7. doi: 10.1080/10428194.2021.1984460.
    PubMed     Abstract available


  70. FULCHER J, Berardi P, Christou G, Villeneuve PJA, et al
    Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2295-2297.
    PubMed    


  71. ARORA S, Vachhani P, Bachiashvili K, Jamy O, et al
    Venetoclax with chemotherapy in relapse/refractory early T-cell precursor acute lymphoblastic leukemia.
    Leuk Lymphoma. 2021;62:2292-2294.
    PubMed    


    August 2021
  72. WANG J, Yang L, Dao FT, Wang YZ, et al
    Prognostic significance of TIM-3 expression pattern at diagnosis in patients with t(8;21) acute myeloid leukemia.
    Leuk Lymphoma. 2021 Aug 18:1-10. doi: 10.1080/10428194.2021.1966785.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Stem Cell Research is free of charge.